OSE Immunotherapeutics S.A.
OSE Immunotherapeutics S.A.
Your view on ORPOF
Overview
What the company does, where it operates, and who runs it.
About OSE Immunotherapeutics S.A.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dominique Costantini
- Headquarters
- 22, boulevard Benoni Goullin, Nantes, FR
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dominique Costantini
- Headquarters
- 22, boulevard Benoni Goullin, Nantes, FR
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.
Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers.
The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation.
OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for OSE Immunotherapeutics S.A., and the rating behind it. ORPOF last traded at $11.60; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for OSE Immunotherapeutics S.A.. Starting points for OSE Immunotherapeutics S.A.: EPS -$1.68, beta 0.83 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for OSE Immunotherapeutics S.A.. OSE Immunotherapeutics S.A. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for OSE Immunotherapeutics S.A.. Trailing twelve-month EPS for OSE Immunotherapeutics S.A. stands at -$1.68. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for OSE Immunotherapeutics S.A.. OSE Immunotherapeutics S.A. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
OSE Immunotherapeutics S.A. valued side by side against its closest peers. OSE Immunotherapeutics S.A. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold OSE Immunotherapeutics S.A., and how their positions are changing. At a $260.3M market value, institutional positions materially move OSE Immunotherapeutics S.A.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by OSE Immunotherapeutics S.A. executives and directors. Shares of OSE Immunotherapeutics S.A. have traded between $11.60 and $11.60 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming OSE Immunotherapeutics S.A.. OSE Immunotherapeutics S.A. is a $260.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming OSE Immunotherapeutics S.A.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for OSE Immunotherapeutics S.A.. Coverage tracks OSE Immunotherapeutics S.A. within Biotechnology (Healthcare). Press releases and market coverage, newest first.